Chronic hepatitis delta virus (HDV) infection

Active Ingredient: Bulevirtide

Indication for Bulevirtide

Population group: only adults (18 years old or older)

Bulevirtide is indicated for the treatment of chronic hepatitis delta virus (HDV) infection in plasma (or serum) HDV-RNA positive adult patients with compensated liver disease.

For this indication, competent medicine agencies globally authorize below treatments:

2 mg once daily

Route of admnistration

Subcutaneous

Defined daily dose

2 - 2 mg

Dosage regimen

From 2 To 2 mg once every day

Detailed description

Bulevirtide should be administered at 2 mg once daily (every 24 h ± 4 h) by subcutaneous injection as monotherapy or in co-administration with a nucleoside/nucleotide analogue for treatment of underlying HBV infection.

Duration of treatment

The optimal treatment duration is unknown. Treatment should be continued as long as associated with clinical benefit.

Consideration to discontinue the treatment should be given in case of sustained (6 months) HBsAg seroconversion or loss of virological and biochemical response.

Missed doses

If an injection has been omitted and less than 4 hours have elapsed since the scheduled time, the injection must be performed as soon as possible. The time of the next injection will not be calculated from the time of the “rescue” injection, but according to the injection schedule previously established. It is, therefore, necessary to return to the usual pattern of administration, at the appointed time, the following day.

If an injection has been missed and more than 4 hours have elapsed since the scheduled time, the missed dose should not be administered.

The next injection will take place according to the usual schedule (injection of the prescribed dose without doubling), at the appointed time the next day.

If the injection has been made by mistake more than 4 hours after the scheduled time, the next administration must take place in the usual way (i.e. in accordance with the original schedule).

Dosage considerations

Bulevirtide may be injected into sites such as the upper thigh, or abdomen.

Active ingredient

Bulevirtide

Bulevirtide blocks the entry of HBV and HDV into hepatocytes by binding to and inactivating NTCP, a bile salt liver transporter serving as essential HBV/HDV entry receptor.

Read more about Bulevirtide

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.